Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 10/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13941746 | 0.85 | AXL (0.50) | AXLMAP2K1BRAFCYP2C19 | |
| SCHEMBL30267564 | 0.85 | AXL (0.50) | AXLMAP2K1BRAFCYP2C19 | |
| SCHEMBL12146867 | 0.84 | CYP2C19 (0.47) | AXLNR4A2MAP2K1BRAFCYP2C19 | |
| SCHEMBL30020999 | 0.83 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPNEK1 | |
| SCHEMBL30676600 | 0.83 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPBRAF | |
| SCHEMBL9938142 | 0.83 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPNEK1 | |
| SCHEMBL9936933 | 0.83 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPBRAF | |
| SCHEMBL1427263 | 0.83 | AXL (0.63) | AXLNR4A2MAP2K1CREBBPBRAF | |
| SCHEMBL15942804 | 0.83 | BRAF (0.45) | AXLNR4A2MAP2K1BRAFCYP2C19 | |
| SCHEMBL19657575 | 0.81 | NTRK1 (0.47) | AXLNR4A2MAP2K1CREBBPBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | AXL 4160/4885NR4A2 3995/4885MAP2K1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.